Barry A. Siegel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Barry A. Siegel has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Bital Savir-Baruch
2 shared publications- Abhinav Kumar Jha
Washington University in St. Louis
1 shared publication - Albert Chau
Blue Earth Diagnostics Ltd, Oxford, UK.
1 shared publication Andrei Purysko
1 shared publication- Ashesh B. Jani
Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA
1 shared publication Ashutosh Tewari
1 shared publication
Latest Publications
- Open Access
ISIT-GEN: An in silico imaging trial to assess the inter-scanner generalizability of CTLESS for myocardial perfusion SPECT on defect-detection task
A recently proposed scatter-window and deep learning-based attenuation compensation (AC) method for myocardial perfusion imaging (MPI) by single-photon emission computed tomography (SPECT), namely CTLESS, demonstrated promising performance on the clinical task of myocardial perfusion defect detection with retrospective data acquired on SPECT scanners from a single vendor. For clinical translation of CTLESS, it is important to assess the generalizability of CTLESS across different SPECT scanners. For this purpose, we conducted a virtual imaging trial, titled in silico imaging trial to assess generalizability (ISIT-GEN). ISIT-GEN assessed the generalizability of CTLESS on the cardiac perfusion defect detection task across SPECT scanners from three different vendors. The performance of CTLESS was compared with a standard-of-care CT-based AC (CTAC) method and a no-attenuation compensation (NAC) method using an anthropomorphic model observer. We observed that CTLESS had receiver operating characteristic (ROC) curves and area under the ROC curves similar to those of CTAC. Further, CTLESS was observed to significantly outperform the NAC method across three scanners. These results are suggestive of the inter-scanner generalizability of CTLESS and motivate further clinical evaluations. The study also highlights the value of using in silico imaging trials to assess the generalizability of deep learning-based AC methods feasibly and rigorously.
Open AccessISIT-GEN: An in silico imaging trial to assess the inter-scanner generalizability of CTLESS for myocardial perfusion SPECT on defect-detection task
A recently proposed scatter-window and deep learning-based attenuation compensation (AC) method for myocardial perfusion imaging (MPI) by single-photon emission computed tomography (SPECT), namely CTLESS, demonstrated promising performance on the clinical task of myocardial perfusion defect detection with retrospective data acquired on SPECT scanners from a single vendor. For clinical translation of CTLESS, it is important to assess the generalizability of CTLESS across different SPECT scanners. For this purpose, we conducted a virtual imaging trial, titled in silico imaging trial to assess generalizability (ISIT-GEN). ISIT-GEN assessed the generalizability of CTLESS on the cardiac perfusion defect detection task across SPECT scanners from three different vendors. The performance of CTLESS was compared with a standard-of-care CT-based AC (CTAC) method and a no-attenuation compensation (NAC) method using an anthropomorphic model observer. We observed that CTLESS had receiver operating characteristic (ROC) curves and area under the ROC curves similar to those of CTAC. Further, CTLESS was observed to significantly outperform the NAC method across three scanners. These results are suggestive of the inter-scanner generalizability of CTLESS and motivate further clinical evaluations. The study also highlights the value of using in silico imaging trials to assess the generalizability of deep learning-based AC methods feasibly and rigorously.
- Open Access
- 1 August 2023
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 210 (2) , 299-311
Diagnostic Performance and Safety of 18 F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)
SPOTLIGHT (NCT04186845) evaluated diagnostic performance and safety of radiohybrid (rh) 18F-rhPSMA-7.3, a novel high-affinity PET radiopharmaceutical. Men with prostate cancer recurrence underwent PET/CT 50-70 minutes after intravenous administration of 296±20% MBq 18F-rhPSMA-7.3. To assess the co-primary endpoints (verified detection rate [VDR] and combined region-level positive predictive value [crPPV]), 3 blinded, independent central readers evaluated the scans. VDR is equivalent to the overall detection rate (DR) x PPV. Standard of Truth (SoT) was established for each patient using histopathology or confirmatory imaging. Statistical thresholds (lower bounds of the confidence intervals) of 36.5% and 62.5% were prespecified for VDR and crPPV, respectively. Additional endpoints included DR, VDR and crPPV in patients with histopathology SoT, and safety. The overall 18F-rhPSMA-7.3 DR among all 389 patients with an evaluable scan was 83% (majority read). Among the 366 patients (median PSA, 1.27 ng/mL) for whom a SOT (histopathology [n=69]/confirmatory imaging only [n=297]) was available, VDR ranged from 51% (95%CI, 46.1-56.6) to 54% (95%, 48.8-59.3), exceeding the prespecified statistical threshold. crPPV ranged from 46% (95%CI, 42.0-50.3%) to 60% (95%CI, 55.1-65.5%) across the readers, not meeting the threshold. In the subset of patients with histopathology SoT, the VDR and crPPV were both above the prespecified thresholds (majority read, 81% [95%CI, 69.9-89.6] and 72% [95%CI, 62.5-80.7], respectively). No significant safety concerns were identified. 18F-rhPSMA-7.3 offers a clinically meaningful VDR for localization of recurrent prostate cancer. Despite missing the co-primary endpoint of crPPV, the totality of the data support the potential clinical utility of 18F-rhPSMA-7.3.
- 1 August 2023
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 210 (2) , 299-311
Open AccessDiagnostic Performance and Safety of 18 F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)
SPOTLIGHT (NCT04186845) evaluated diagnostic performance and safety of radiohybrid (rh) 18F-rhPSMA-7.3, a novel high-affinity PET radiopharmaceutical. Men with prostate cancer recurrence underwent PET/CT 50-70 minutes after intravenous administration of 296±20% MBq 18F-rhPSMA-7.3. To assess the co-primary endpoints (verified detection rate [VDR] and combined region-level positive predictive value [crPPV]), 3 blinded, independent central readers evaluated the scans. VDR is equivalent to the overall detection rate (DR) x PPV. Standard of Truth (SoT) was established for each patient using histopathology or confirmatory imaging. Statistical thresholds (lower bounds of the confidence intervals) of 36.5% and 62.5% were prespecified for VDR and crPPV, respectively. Additional endpoints included DR, VDR and crPPV in patients with histopathology SoT, and safety. The overall 18F-rhPSMA-7.3 DR among all 389 patients with an evaluable scan was 83% (majority read). Among the 366 patients (median PSA, 1.27 ng/mL) for whom a SOT (histopathology [n=69]/confirmatory imaging only [n=297]) was available, VDR ranged from 51% (95%CI, 46.1-56.6) to 54% (95%, 48.8-59.3), exceeding the prespecified statistical threshold. crPPV ranged from 46% (95%CI, 42.0-50.3%) to 60% (95%CI, 55.1-65.5%) across the readers, not meeting the threshold. In the subset of patients with histopathology SoT, the VDR and crPPV were both above the prespecified thresholds (majority read, 81% [95%CI, 69.9-89.6] and 72% [95%CI, 62.5-80.7], respectively). No significant safety concerns were identified. 18F-rhPSMA-7.3 offers a clinically meaningful VDR for localization of recurrent prostate cancer. Despite missing the co-primary endpoint of crPPV, the totality of the data support the potential clinical utility of 18F-rhPSMA-7.3.
- 1 March 2021
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 216 (3) , W10
Using 18F-Fluciclovine PET/CT to Detect Prostate Cancer Recurrence in Patients With Very Low PSA Levels
- 1 March 2021
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 216 (3) , W10
Using 18F-Fluciclovine PET/CT to Detect Prostate Cancer Recurrence in Patients With Very Low PSA Levels
- Open Access
- 11 January 2018
- Published by Codon Publications in Journal of Kidney Cancer
- Vol. 5 (1) , 1-6
Extensive Metastatic Sarcomatoid Renal Cell Carcinoma Evaluated by 18F-FDG PET/CT: a Case Report and Review of Literature
Sarcomatoid renal cell carcinoma (sRCC) is a highly aggressive form of dedifferentiated renal cell carcinoma. We report a 62-yearold man who presented with respiratory symptoms and a lung mass on chest computed tomography (CT). The patient underwent positron emission tomography/computed tomography (PET/CT) with 18F-fluorodeoxyglucose (18F-FDG) and was found to have extensive metastatic disease. Based on the history and imaging findings, there were possible primary malignancies, including bronchogenic carcinoma, melanoma, or an aggressive lymphoma. An excisional biopsy surprisingly revealed a high-grade sarcomatoid carcinoma with no evidence of differentiation, and immunohistochemical (IHC) studies showed that the tumor cells were positive for markers of genitourinary origin (PAX-8 and vimentin). The histologic and IHC results, along with multiple FDG-avid exophytic lesions in both kidneys, were considered diagnostic of sRCC. Here we have highlighted the potential role of 18F-FDG-PET-CT in patients with sRCC, discussed the diagnostic challenges, and presented a brief review.
- 11 January 2018
- Published by Codon Publications in Journal of Kidney Cancer
- Vol. 5 (1) , 1-6
Open AccessExtensive Metastatic Sarcomatoid Renal Cell Carcinoma Evaluated by 18F-FDG PET/CT: a Case Report and Review of Literature
Sarcomatoid renal cell carcinoma (sRCC) is a highly aggressive form of dedifferentiated renal cell carcinoma. We report a 62-yearold man who presented with respiratory symptoms and a lung mass on chest computed tomography (CT). The patient underwent positron emission tomography/computed tomography (PET/CT) with 18F-fluorodeoxyglucose (18F-FDG) and was found to have extensive metastatic disease. Based on the history and imaging findings, there were possible primary malignancies, including bronchogenic carcinoma, melanoma, or an aggressive lymphoma. An excisional biopsy surprisingly revealed a high-grade sarcomatoid carcinoma with no evidence of differentiation, and immunohistochemical (IHC) studies showed that the tumor cells were positive for markers of genitourinary origin (PAX-8 and vimentin). The histologic and IHC results, along with multiple FDG-avid exophytic lesions in both kidneys, were considered diagnostic of sRCC. Here we have highlighted the potential role of 18F-FDG-PET-CT in patients with sRCC, discussed the diagnostic challenges, and presented a brief review.